Fidelity Investments
CCCC icon

Fidelity Investments’s C4 Therapeutics CCCC Stock Holding History

Fidelity Investments’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$716K Buy
272,368
+17,962
+7% +$42.3K ﹤0.01% 2983
2025
Q4 		$486K Buy
254,406
+43,058
+20% +$102K ﹤0.01% 3097
2025
Q3 		$469K Buy
211,348
+9,990
+5% +$24K ﹤0.01% 3054
2025
Q2 		$288K Buy
201,358
+7,608
+4% +$11.1K ﹤0.01% 3176
2025
Q1 		$310K Sell
193,750
-24,615
-11% -$73.4K ﹤0.01% 3077
2024
Q4 		$786K Buy
218,365
+32,424
+17% +$161K ﹤0.01% 2758
2024
Q3 		$1.06M Buy
185,941
+162,314
+687% +$977K ﹤0.01% 2581
2024
Q2 		$109K Sell
23,627
-13,661
-37% -$81.5K ﹤0.01% 3264
2024
Q1 		$305K Sell
37,288
-272
-0.7% -$2.11K ﹤0.01% 2879
2023
Q4 		$212K Sell
37,560
-83,605
-69% -$191K ﹤0.01% 2947
2023
Q3 		$225K Buy
121,165
+66,398
+121% +$203K ﹤0.01% 2858
2023
Q2 		$151K Sell
54,767
-335
-0.6% -$1.08K ﹤0.01% 3027
2023
Q1 		$173K Buy
55,102
+2,763
+5% +$16.3K ﹤0.01% 3032
2022
Q4 		$309K Sell
52,339
-5,181
-9% -$43K ﹤0.01% 2873
2022
Q3 		$504K Buy
57,520
+56,210
+4,291% +$584K ﹤0.01% 2780
2022
Q2 		$10K Sell
1,310
-597,971
-100% -$5.26M ﹤0.01% 4104
2022
Q1 		$14.5M Sell
599,281
-49,700
-8% -$1.21M ﹤0.01% 1946
2021
Q4 		$20.9M Hold
648,981
– – ﹤0.01% 1804
2021
Q3 		$29M Buy
648,981
+69,700
+12% +$2.98M ﹤0.01% 1666
2021
Q2 		$21.9M Buy
579,281
+240,894
+71% +$8.63M ﹤0.01% 1817
2021
Q1 		$12.5M Sell
338,387
-332,900
-50% -$13.2M ﹤0.01% 1962
2020
Q4 		$22.2M Buy
+671,287
New +$19.5M ﹤0.01% 1674

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments's CCCC Position: Q1 2026 in Review

Fidelity Investments increased its C4 Therapeutics (CCCC) stake by 7.1% in Q1 2026, buying an estimated $42.3K and bringing the position to 272,368 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #2983.

Fidelity Investments first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $29M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Fidelity Investments held 272,368 shares of C4 Therapeutics worth $716K as of Q1 2026.
  • Fidelity Investments bought 17,962 C4 Therapeutics shares in Q1 2026, an estimated $42.3K.
  • C4 Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2983 holding.
  • Fidelity Investments first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Fidelity Investments's C4 Therapeutics position peaked at $29M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.